Loading patent…
AssigneeCue Biopharma, Inc.
InventorsRonald D. Seidel, III, Rodolfo J. Chaparro, John F. Ross, Chee Meng Low
Estimating the term…
The present disclosure provides T-cell modulatory multimeric polypeptides (“T-Cell-MMPs”) comprising an immunomodulatory polypeptide (“MOD”) that may be selected to exhibit reduced binding affinity to a cognate co-immunomodulatory polypeptide (“Co-MOD”) and a location for covalently attaching a molecule that can serve as an epitope, such as an epitope peptide. Once the epitope molecule is attached the resulting T-Cell-MMP-epitope conjugates are useful for modulating the activity of a T-cell by delivering immunomodulatory peptides, such as IL-2 or IL-2 variants that exhibit reduced binding affinity for IL-2R, to the T-cells in an epitope selective/specific manner, and accordingly, for modulating an immune response in an individual.
A T-cell modulatory multimeric polypeptide (T-Cell-MMP) comprising:
Dependencies are inferred from the claim text.